Free Trial

Allakos (ALLK) Stock Price, News & Analysis

-0.05 (-4.27%)
(As of 06/18/2024 ET)
Today's Range
50-Day Range
52-Week Range
234,019 shs
Average Volume
440,503 shs
Market Capitalization
$99.16 million
P/E Ratio
Dividend Yield
Price Target

Allakos MarketRank™ Stock Analysis

Analyst Rating
2.20 Rating Score
63.7% Upside
$1.83 Price Target
Short Interest
5.69% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($1.24) to ($0.69) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.40 out of 5 stars

Medical Sector

232nd out of 906 stocks

Pharmaceutical Preparations Industry

102nd out of 428 stocks

ALLK stock logo

About Allakos Stock (NASDAQ:ALLK)

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

ALLK Stock Price History

ALLK Stock News Headlines

The attacks will come for me after releasing this…
For decades, one group in Washington, D.C., has been solidifying its power behind the scenes. Stoking political division… attacking capitalism… starting wars... this group has done everything in its power to gain more control…
The attacks will come for me after releasing this…
For decades, one group in Washington, D.C., has been solidifying its power behind the scenes. Stoking political division… attacking capitalism… starting wars... this group has done everything in its power to gain more control…
3 Biotech Stocks to Dump Before They Go to Zero
Hold Rating on Allakos Amidst Cautious Optimism for AK006 Program
TD Cowen Remains a Hold on Allakos (ALLK)
ALLK Stock Earnings: Allakos Misses EPS for Q4 2023
ALLK Sep 2024 2.000 call
ALLK Sep 2024 2.500 call
ALLK Mar 2024 1.500 call
See More Headlines
Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.93 per share


Free Float
Market Cap
$99.16 million
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Robert Alexander Ph.D. (Age 54)
    CEO & Director
    Comp: $1.5M
  • Dr. Adam L. Tomasi Ph.D. (Age 54)
    Comp: $1.15M
  • Mr. Baird Radford III (Age 54)
    Chief Financial Officer
    Comp: $731.35k
  • Ms. Mary Cromwell Ph.D.
    Chief Technical Officer
  • Dr. Chin Lee M.D. (Age 54)
    M.P.H., Chief Medical Officer
  • Mr. Alan Chang
    Director of Medical Affairs & Data Analytics

ALLK Stock Analysis - Frequently Asked Questions

Should I buy or sell Allakos stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.
View ALLK analyst ratings
or view top-rated stocks.

What is Allakos' stock price target for 2024?

5 Wall Street analysts have issued 12 month target prices for Allakos' shares. Their ALLK share price targets range from $1.00 to $3.00. On average, they predict the company's share price to reach $1.83 in the next year. This suggests a possible upside of 63.7% from the stock's current price.
View analysts price targets for ALLK
or view top-rated stocks among Wall Street analysts.

How have ALLK shares performed in 2024?

Allakos' stock was trading at $2.73 on January 1st, 2024. Since then, ALLK shares have decreased by 59.0% and is now trading at $1.12.
View the best growth stocks for 2024 here

When is Allakos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our ALLK earnings forecast

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) posted its earnings results on Thursday, May, 9th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.09.

What other stocks do shareholders of Allakos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

When did Allakos IPO?

Allakos (ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

Who are Allakos' major shareholders?

Allakos' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (18.69%), Vanguard Group Inc. (4.29%), Redmile Group LLC (3.90%), Opaleye Management Inc. (2.75%), Acadian Asset Management LLC (1.50%) and Platinum Investment Management Ltd. (1.32%). Insiders that own company stock include Paul Edward Walker and Steven P James.
View institutional ownership trends

How do I buy shares of Allakos?

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALLK) was last updated on 6/19/2024 by Staff

From Our Partners